Aplos Medical

Aplos Medical, formerly known as CT Resources, is a medical device company focused on developing treatments for gastroesophageal reflux disease (GERD). Founded in 2019 and headquartered in Eden Prairie, MN, the company is led by President and CEO, Dr. Claude Tihon. The company's core product is the Omega PF™, an investigational, Ω-shaped implantable device designed to be a next-generation treatment for GERD.

The Omega PF™ is implanted via a laparoscopic procedure and is engineered to control acid reflux while preserving the natural swallowing process, a feature intended to minimize side effects like dysphagia that can be common with other GERD treatments. This dual-modality approach aims to benefit patients, surgeons, and healthcare payers. The company operates in the multi-billion dollar GERD market and targets its device toward surgeons as a simpler and swifter procedure compared to traditional options like Nissen fundoplication.

A significant milestone was achieved in August 2023 with the first successful implantation of the Omega PF™ device in a patient at the Dell Medical Center of the University of Texas at Austin. The procedure was part of a clinical feasibility study supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a part of the National Institutes of Health (NIH). Aplos Medical has received funding through grants, including two rounds from HHS in 2019 and 2021 totaling over $3.3M, and investment from accelerator MNSBIR.

Keywords: GERD treatment, laparoscopic implant, acid reflux, medical device, therapeutic devices, Omega PF, Claude Tihon, dysphagia, anti-reflux surgery, esophageal disease, clinical trials, medtech, surgical devices, NIDDK, NIH grant, minimally invasive surgery, gastroenterology, digestive health, surgical innovation, medical implants.